Provided by Tiger Fintech (Singapore) Pte. Ltd.

MaxCyte Inc

2.79
-0.0500-1.76%
Post-market: 2.76-0.0300-1.08%16:10 EDT
Volume:315.95K
Turnover:887.35K
Market Cap:296.62M
PE:-7.13
High:2.88
Open:2.85
Low:2.76
Close:2.84
Loading ...

Top Premarket Gainers

MT Newswires Live
·
Yesterday

MaxCyte Announces AIM Delisting to Focus on NASDAQ

TIPRANKS
·
28 Apr

BlackRock Adjusts Stake in MaxCyte, Inc.

TIPRANKS
·
22 Apr

MaxCyte Announces Change in Major Shareholder Holdings

TIPRANKS
·
22 Apr

MaxCyte Announces Change in Major Holdings by BlackRock

TIPRANKS
·
16 Apr

Craig-Hallum Sticks to Its Buy Rating for MaxCyte (MXCT)

TIPRANKS
·
15 Apr

MaxCyte to Propose AIM Delisting to Shareholders

Dow Jones
·
15 Apr

BRIEF-Maxcyte Proposes Cancellation Of AIM Listing, Continues Nasdaq Listing

Reuters
·
15 Apr

MaxCyte Inc - Proposes Cancellation of Aim Listing, Continues Nasdaq Listing

THOMSON REUTERS
·
15 Apr

MaxCyte Announces Change in Voting Rights Structure

TIPRANKS
·
14 Apr

MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025

GlobeNewswire
·
10 Apr

MaxCyte Announces Change in Major Holdings by BlackRock

TIPRANKS
·
08 Apr

With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns

Simply Wall St.
·
08 Apr

Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a Turnaround

Zacks
·
07 Apr

MaxCyte (MXCT) Upgraded to Buy: Here's What You Should Know

Zacks
·
05 Apr

MaxCyte Announces CFO’s RSU Vesting and Share Sale

TIPRANKS
·
26 Mar

MaxCyte management to meet with BTIG

TIPRANKS
·
20 Mar

BlackRock Increases Stake in MaxCyte to 7.71%

TIPRANKS
·
19 Mar

BRIEF-Maxcyte Sees 2025 Core Revenue To Grow 8% To 15%

Reuters
·
12 Mar

MaxCyte Inc (MXCT) Q4 2024 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges

GuruFocus.com
·
12 Mar